Sopharma AD (BUL:SFA)

Bulgaria · Delayed Price · Currency is EUR

3.320

+0.120 (3.75%)

At close: Oct 23, 2026

Market Cap	1.79B +149.7%
Revenue (ttm)	1.45B +17.4%
Net Income	85.04M +64.9%
EPS	0.23 +121.8%
Shares Out	538.41M
PE Ratio	14.59
Forward PE	n/a
Dividend	0.14 (4.22%)
Ex-Dividend Date	Jul 9, 2026

Volume	41,241
Open	3.200
Previous Close	3.200
Day's Range	3.200 - 3.370
52-Week Range	1.340 - 3.320
Beta	0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 6,049

Stock Exchange Bulgarian Stock Exchange

Ticker Symbol SFA

Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial Statements